August inspection drew four Form-483 observations; regulator classifies as Voluntary Action Indicated. Hyderabad Natco Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its FDF manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh. The US regulator conducted the inspection at the plant during August 17-21, 2026. “On conclusion of the inspection, the Company had received four observations in the Form-483.